Streetbeat News

Revenues

IGMS

IGM Biosciences (NASDAQ:IGMS) has seen a variety of analyst opinions over the past three months, with recent ratings showing a shift towards a more bullish outlook. Analysts have set a 12-month price target average of $17.5 for IGMS, marking a significant increase from the previous $9.00 average. This change reflects a positive sentiment based on the company's performance and market conditions. IGM Biosciences is a biotech firm focused on developing antibody therapeutics for various diseases, showing strong revenue growth but facing challenges in net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

March 08, 2024 | 8:01 pm

MEDP

Medpace Holdings (NASDAQ:MEDP) has received diverse analyst ratings over the last three months, with a shift towards a more bullish outlook. The average 12-month price target for MEDP has increased by 22.55% to $413.0. Analysts from UBS and Baird have raised their price targets, reflecting positive sentiment towards the company's performance, including a solid revenue growth rate of 26.47% and a high net margin of 15.7%. Medpace, a contract research organization, has shown strong financial management with an ROE of 15.2% and an ROA of 4.98%.

Portfolio Pulse from Benzinga Insights

March 08, 2024 | 8:01 pm

FHI

Seven analysts have recently updated their ratings on Federated Hermes (NYSE:FHI), showing a mix of perspectives with an average 12-month price target of $37.14, up from $36.80. The updates include raised price targets and ratings, reflecting a cautiously optimistic outlook on the company's performance. Federated Hermes, with $757.6 billion in managed assets, shows a positive revenue trend and strong financial performance indicators such as ROE and ROA, despite a market capitalization below industry averages and a net margin below benchmarks.

Portfolio Pulse from Benzinga Insights

March 08, 2024 | 8:00 pm

EYPT

EyePoint Pharmaceuticals (NASDAQ:EYPT) has received diverse analyst ratings over the past quarter, with a shift towards more bullish sentiments in the last 30 days. The average 12-month price target for EYPT has increased by 12.64% to $36.8, with a high estimate of $44.00 and a low estimate of $33.00. Financial analysis reveals a positive revenue trend with a growth rate of 51.84% as of September 30, 2023, but challenges in net margin, ROE, and ROA. The company's debt-to-equity ratio is below industry average, indicating a conservative financial approach.

Portfolio Pulse from Benzinga Insights

March 08, 2024 | 8:00 pm

AAPL

GFS

NVDA

TSM

Taiwan Semiconductor Manufacturing Corp. (TSMC) is expected to receive up to $5 billion in grants from the U.S. government for a chip fabrication facility in Arizona to meet the demand from major customers like Apple and Nvidia. The facility is part of TSMC's $40 billion investment in semiconductor manufacturing in Phoenix, aiming to start production in 2025. This move aligns with the U.S. CHIPS Act's goal to boost domestic semiconductor production.

Portfolio Pulse from Neil Dennis

March 08, 2024 | 7:39 pm

BC

Seven analysts have recently updated their ratings on Brunswick (NYSE:BC), showing a shift towards a more bullish outlook with an average 12-month price target of $105.71, up from $95.50. The updates include raised price targets and ratings, reflecting positive sentiment towards Brunswick's market position despite a -13.95% decline in revenue growth and a high debt-to-equity ratio. Brunswick is recognized for its innovation in the marine recreation industry, with a strong market capitalization and financial health indicators like net margin, ROE, and ROA outperforming industry averages.

Portfolio Pulse from Benzinga Insights

March 08, 2024 | 7:01 pm

DOCU

In the last three months, 13 analysts have published diverse ratings on DocuSign (NASDAQ:DOCU), with recent updates showing a mix of opinions. The average 12-month price target has been raised to $64.62, indicating a 21.65% increase from the previous target. Analysts' actions, including maintaining, raising, and lowering ratings, reflect their current views on the company's performance and market conditions. DocuSign's financial health is analyzed, highlighting its market capitalization, revenue growth, net margin, ROE, ROA, and debt management. The company's Agreement Cloud offers a suite for automating agreements and providing e-signatures.

Portfolio Pulse from Benzinga Insights

March 08, 2024 | 7:01 pm

AR

Antero Resources (NYSE:AR) has been analyzed by 7 analysts, showing a mix of bullish to bearish sentiments. The average 12-month price target is $28.00, down 7.68% from the previous target. Analyst actions include both upgrades and downgrades, reflecting varying perspectives on the company's performance. Antero Resources, engaged in natural gas and liquids production, faces challenges with lower market capitalization, revenue decline of -38.57%, and below-average profitability and efficiency metrics.

Portfolio Pulse from Benzinga Insights

March 08, 2024 | 7:01 pm

PLXS

Analysts have diverse opinions on Plexus (NASDAQ:PLXS), with recent ratings ranging from bullish to indifferent. The average 12-month price target is now $109.8, down from $111.50. Plexus faces revenue challenges with a -10.18% decline as of December 31, 2023, but outperforms in net margin, ROE, and ROA. The company's debt management is also noted positively.

Portfolio Pulse from Benzinga Insights

March 08, 2024 | 7:00 pm

TYL

Tyler Technologies (NYSE:TYL) has received mixed analyst ratings over the past three months, with a total of 10 ratings ranging from bullish to bearish. The average 12-month price target for TYL has increased by 5.3% to $491.5. Analyst actions include maintaining, raising, and announcing ratings, with price targets adjusted accordingly. Tyler Technologies, a provider of software solutions for local government entities, has shown a revenue growth of 6.35% as of December 31, 2023, but trails behind industry peers in profitability and efficiency metrics.

Portfolio Pulse from Benzinga Insights

March 08, 2024 | 7:00 pm